Ferroptosis-centered Drug Response Information
General Information of the Drug (ID: ferrodrug0290)
Name |
Bavachin
|
||||
---|---|---|---|---|---|
Synonyms |
Bavachin; 19879-32-4; Corylifolin; (S)-7-Hydroxy-2-(4-hydroxyphenyl)-6-(3-methylbut-2-en-1-yl)chroman-4-one; 4H-1-Benzopyran-4-one, 2,3-dihydro-7-hydroxy-2-(4-hydroxyphenyl)-6-(3-methyl-2-butenyl)-, (2S)-; CORYFOLIN; CHEMBL469444; SCHEMBL4223610; HY-N0233; MFCD11617359; NSC808860; s5469; AKOS032962062; CCG-267746; CS-6113; NSC-808860; AC-34020; AS-75959; A879959; 7-Hydroxy-2-(4-hydroxyphenyl)-6-(3-methylbut-2-en-1-yl)chroman-4-one
Click to Show/Hide
|
||||
Structure |
![]() |
||||
Formula |
C20H20O4
|
||||
IUPAC Name |
(2S)-7-hydroxy-2-(4-hydroxyphenyl)-6-(3-methylbut-2-enyl)-2,3-dihydrochromen-4-one
|
||||
Canonical SMILES |
CC(=CCC1=CC2=C(C=C1O)OC(CC2=O)C3=CC=C(C=C3)O)C
|
||||
InChI |
InChI=1S/C20H20O4/c1-12(2)3-4-14-9-16-18(23)11-19(24-20(16)10-17(14)22)13-5-7-15(21)8-6-13/h3,5-10,19,21-22H,4,11H2,1-2H3/t19-/m0/s1
|
||||
InChIKey |
OAUREGNZECGNQS-IBGZPJMESA-N
|
||||
PubChem CID |
Full List of Ferroptosis Target Related to This Drug
Cystine/glutamate transporter (SLC7A11)
In total 2 item(s) under this Target | ||||
Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target | [1] | |||
Target for Ferroptosis | Suppressor | |||
Responsed Disease | Osteosarcoma | ICD-11: 2B51 | ||
Responsed Regulator | Signal transducer and activator of transcription 3 (STAT3) | Suppressor | ||
Pathway Response | Ferroptosis | hsa04216 | ||
Cell Process | Cell ferroptosis | |||
In Vitro Model | MG-63 cells | Osteosarcoma | Homo sapiens | CVCL_0426 |
HOS cells | Osteosarcoma | Homo sapiens | CVCL_0312 | |
Response regulation | Bavachin could induce Osteosarcoma cell ferroptosis. Furthermore, bavachin elevated intracellular ferrous iron levels by increasing TFRC and DMT1 expression and decreasing FTH and FTL expressions. Bavachin also reduced SLC7A11 and GPX4 expression and promoted ROS and MDA accumulation by downregulating p-STAT3 to upregulate P53 expression. | |||
Experiment 2 Reporting the Ferroptosis-centered Drug Act on This Target | [1] | |||
Target for Ferroptosis | Suppressor | |||
Responsed Disease | Osteosarcoma | ICD-11: 2B51 | ||
Responsed Regulator | Cellular tumor antigen p53 (TP53) | Driver | ||
Pathway Response | Ferroptosis | hsa04216 | ||
Cell Process | Cell ferroptosis | |||
In Vitro Model | MG-63 cells | Osteosarcoma | Homo sapiens | CVCL_0426 |
HOS cells | Osteosarcoma | Homo sapiens | CVCL_0312 | |
Response regulation | Bavachin could induce Osteosarcoma cell ferroptosis. Furthermore, bavachin elevated intracellular ferrous iron levels by increasing TFRC and DMT1 expression and decreasing FTH and FTL expressions. Bavachin also reduced SLC7A11 and GPX4 expression and promoted ROS and MDA accumulation by downregulating p-STAT3 to upregulate P53 expression. | |||
Transferrin receptor protein 1 (TFRC)
In total 1 item(s) under this Target | ||||
Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target | [1] | |||
Target for Ferroptosis | Marker/Suppressor/Driver | |||
Responsed Disease | Osteosarcoma | ICD-11: 2B51 | ||
Pathway Response | Ferroptosis | hsa04216 | ||
Cell Process | Cell ferroptosis | |||
In Vitro Model | MG-63 cells | Osteosarcoma | Homo sapiens | CVCL_0426 |
HOS cells | Osteosarcoma | Homo sapiens | CVCL_0312 | |
Response regulation | Bavachin could induce Osteosarcoma cell ferroptosis. Furthermore, bavachin elevated intracellular ferrous iron levels by increasing TFRC and DMT1 expression and decreasing FTH and FTL expressions. Bavachin also reduced SLC7A11 and GPX4 expression and promoted ROS and MDA accumulation by downregulating p-STAT3 to upregulate P53 expression. | |||
Natural resistance-associated macrophage protein 2 (SLC11A2)
In total 1 item(s) under this Target | ||||
Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target | [1] | |||
Target for Ferroptosis | Driver | |||
Responsed Disease | Osteosarcoma | ICD-11: 2B51 | ||
Pathway Response | Ferroptosis | hsa04216 | ||
Cell Process | Cell ferroptosis | |||
In Vitro Model | MG-63 cells | Osteosarcoma | Homo sapiens | CVCL_0426 |
HOS cells | Osteosarcoma | Homo sapiens | CVCL_0312 | |
Response regulation | Bavachin could induce Osteosarcoma cell ferroptosis. Furthermore, bavachin elevated intracellular ferrous iron levels by increasing TFRC and DMT1 (SLC11A2) expression and decreasing FTH and FTL expressions. Bavachin also reduced SLC7A11 and GPX4 expression and promoted ROS and MDA accumulation by downregulating p-STAT3 to upregulate P53 expression. | |||
Ferritin light chain (FTL)
In total 1 item(s) under this Target | ||||
Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target | [1] | |||
Target for Ferroptosis | Suppressor | |||
Responsed Disease | Osteosarcoma | ICD-11: 2B51 | ||
Pathway Response | Ferroptosis | hsa04216 | ||
Cell Process | Cell ferroptosis | |||
In Vitro Model | MG-63 cells | Osteosarcoma | Homo sapiens | CVCL_0426 |
HOS cells | Osteosarcoma | Homo sapiens | CVCL_0312 | |
Response regulation | Bavachin could induce Osteosarcoma cell ferroptosis. Furthermore, bavachin elevated intracellular ferrous iron levels by increasing TFRC and DMT1 expression and decreasing FTH and FTL expressions. Bavachin also reduced SLC7A11 and GPX4 expression and promoted ROS and MDA accumulation by downregulating p-STAT3 to upregulate P53 expression. | |||
Ferritin heavy chain (FTH1)
In total 1 item(s) under this Target | ||||
Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target | [1] | |||
Target for Ferroptosis | Marker/Suppressor | |||
Responsed Disease | Osteosarcoma | ICD-11: 2B51 | ||
Pathway Response | Ferroptosis | hsa04216 | ||
Cell Process | Cell ferroptosis | |||
In Vitro Model | MG-63 cells | Osteosarcoma | Homo sapiens | CVCL_0426 |
HOS cells | Osteosarcoma | Homo sapiens | CVCL_0312 | |
Response regulation | Bavachin could induce Osteosarcoma cell ferroptosis. Furthermore, bavachin elevated intracellular ferrous iron levels by increasing TFRC and DMT1 expression and decreasing FTH and FTL expressions. Bavachin also reduced SLC7A11 and GPX4 expression and promoted ROS and MDA accumulation by downregulating p-STAT3 to upregulate P53 expression. | |||